Psychology
Neuroimaging Biomarkers of Post-Traumatic Stress Disorder
Quick fact
People with PTSD show an average reduction in hippocampal volume of about 5-10% compared to healthy controls, as revealed by structural MRI.
Why this is interesting
What if we could see the invisible scars of trauma on the brain? Neuroimaging is making this possible for post-traumatic stress disorder.
Read the full explanation
Understanding Neuroimaging Biomarkers of Post-Traumatic Stress Disorder
Imagine looking at a photograph of a brain. For someone with post-traumatic stress disorder (PTSD), certain regions appear different: the hippocampus, which helps form memories, often looks smaller; the amygdala, which processes fear, shows more activity; and the prefrontal cortex, which helps control fear, seems less active. These changes are not just in one person—they are consistent patterns across many studies. Neuroimaging biomarkers are like visible signs on a brain scan that correlate with having PTSD. They come from different types of scans: structural MRI shows shape and size, functional MRI shows which areas are active during a task, and other methods reveal chemical makeup. Even though every brain is unique, these group differences are statistically meaningful, suggesting they could be used as a biological indicator of the disorder.
A deeper explanation
Why do these brain changes occur? PTSD is a stress-related disorder. Chronic stress and trauma can damage the hippocampus through elevated cortisol levels, which reduce neurogenesis and shrink dendrites. The amygdala, which starts the fear response, becomes overly reactive, even to non-threatening stimuli, because the prefrontal cortex—which normally puts on the brakes—fails to inhibit it. This creates a vicious cycle: the emotional response overwhelms cognitive control, making the person feel constantly on edge and re-experiencing the trauma. Importantly, these biomarkers are not static: they may change with effective treatment, such as exposure therapy, which can normalize activity in the prefrontal cortex and amygdala. Thus, neuroimaging biomarkers offer a window into the pathophysiology of PTSD, aiding in diagnosis, monitoring progression, and predicting who might benefit from specific therapies.